People | February 20, 2022
Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Subscribe To Our Newsletter & Stay Updated
